Carlos Esteban Builes Montaño
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Carlos Esteban Builes Montaño has a total of 356 co-authors. Here are the top co-authors by number of shared publications:
- Alejandro Román-González
Faculty of Medicine, Universidad de Antioquia, Medellín, Colombia
16 shared publications - Alex Ramírez-Rincón
Universidad Pontificia Bolivariana, Medellín, Colombia
6 shared publications - Jose Garcia-Tirado
Diabetes Center Berne, Berne, Switzerland
6 shared publications - Laura Lema-Perez
Norwegian University of Science and Technology (NTNU)
6 shared publications - Henry Tovar Cortés
Fundación Universitaria de Ciencias de la Salud, Bogotá, Colombia; Hospital San José, Bogotá, Colombia
5 shared publications - Katherine Restrepo Erazo
Universidad Santiago de Cali, Cali, Colombia
5 shared publications
Latest Publications
- Open Access
- 10 November 2026
- Published by Springer Nature in Research Square
Defining Inadequate Control and Clinical Candidacy for PTH Replacement in Chronic Hypoparathyroidism: A Focused Systematic Review
Background Chronic hypoparathyroidism is conventionally treated with calcium and activated vitamin D, but a subset of patients remains insufficiently controlled despite therapy. Definitions of inadequate control and criteria for considering parathyroid hormone (PTH) replacement vary across guidelines, consensus documents, and clinical studies. This review aimed to characterize these criteria and summarize the evidence relevant to PTH replacement in adults with chronic hypoparathyroidism. Methods We conducted a focused systematic review with structured narrative synthesis of normative, secondary, and primary clinical evidence. PubMed/MEDLINE and Embase were searched from inception through July 2026, supplemented by backward citation searching. Technology-assisted screening and extraction were performed within a human-in-the-loop workflow. Definitions, operational criteria, quantitative thresholds, clinical candidacy for PTH replacement, trial eligibility criteria, and treatment outcomes were extracted and synthesized descriptively. No meta-analysis, formal risk-of-bias assessment, or GRADE certainty rating was performed. Results Of 1,618 records identified, 164 reports were included. Inadequate control with conventional therapy was addressed in 108 reports, but only 24 provided an explicit textual definition. The most frequently represented domains were biochemical control (96/108, 88.9%), clinical manifestations (67/108, 62.0%), renal risk or complications (55/108, 50.9%), treatment burden (44/108, 40.7%), and patient-reported outcomes or quality of life (34/108, 31.5%). Quantitative thresholds were reported in 45 reports and persistence or repeated-occurrence requirements in 29, with substantial variability across sources. Fourteen reports directly addressed clinical candidacy for PTH replacement and were organized into 12 framework or guideline-version groupings. Recurrent candidacy domains included symptomatic or unstable calcium control, phosphate abnormalities, renal complications, high treatment requirements, impaired quality of life, malabsorption, and treatment intolerance. Sixty-seven primary reports evaluated PTH-based treatment outcomes. Across study programs, PTH replacement reduced conventional calcium and active vitamin D requirements and showed favorable biochemical, renal, and patient-reported outcomes in selected populations, although long-term comparative evidence and head-to-head data across formulations remained limited. Conclusions Inadequate control of chronic hypoparathyroidism is consistently represented as a multidimensional construct, but no single definition, threshold set, persistence requirement, or eligibility algorithm is universally accepted. This review provides an evidence framework to inform subsequent structured expert deliberation for a Colombian position statement, while preserving areas of uncertainty for explicit panel judgment.
- 10 November 2026
- Published by Springer Nature in Research Square
Open AccessDefining Inadequate Control and Clinical Candidacy for PTH Replacement in Chronic Hypoparathyroidism: A Focused Systematic Review
Background Chronic hypoparathyroidism is conventionally treated with calcium and activated vitamin D, but a subset of patients remains insufficiently controlled despite therapy. Definitions of inadequate control and criteria for considering parathyroid hormone (PTH) replacement vary across guidelines, consensus documents, and clinical studies. This review aimed to characterize these criteria and summarize the evidence relevant to PTH replacement in adults with chronic hypoparathyroidism. Methods We conducted a focused systematic review with structured narrative synthesis of normative, secondary, and primary clinical evidence. PubMed/MEDLINE and Embase were searched from inception through July 2026, supplemented by backward citation searching. Technology-assisted screening and extraction were performed within a human-in-the-loop workflow. Definitions, operational criteria, quantitative thresholds, clinical candidacy for PTH replacement, trial eligibility criteria, and treatment outcomes were extracted and synthesized descriptively. No meta-analysis, formal risk-of-bias assessment, or GRADE certainty rating was performed. Results Of 1,618 records identified, 164 reports were included. Inadequate control with conventional therapy was addressed in 108 reports, but only 24 provided an explicit textual definition. The most frequently represented domains were biochemical control (96/108, 88.9%), clinical manifestations (67/108, 62.0%), renal risk or complications (55/108, 50.9%), treatment burden (44/108, 40.7%), and patient-reported outcomes or quality of life (34/108, 31.5%). Quantitative thresholds were reported in 45 reports and persistence or repeated-occurrence requirements in 29, with substantial variability across sources. Fourteen reports directly addressed clinical candidacy for PTH replacement and were organized into 12 framework or guideline-version groupings. Recurrent candidacy domains included symptomatic or unstable calcium control, phosphate abnormalities, renal complications, high treatment requirements, impaired quality of life, malabsorption, and treatment intolerance. Sixty-seven primary reports evaluated PTH-based treatment outcomes. Across study programs, PTH replacement reduced conventional calcium and active vitamin D requirements and showed favorable biochemical, renal, and patient-reported outcomes in selected populations, although long-term comparative evidence and head-to-head data across formulations remained limited. Conclusions Inadequate control of chronic hypoparathyroidism is consistently represented as a multidimensional construct, but no single definition, threshold set, persistence requirement, or eligibility algorithm is universally accepted. This review provides an evidence framework to inform subsequent structured expert deliberation for a Colombian position statement, while preserving areas of uncertainty for explicit panel judgment.
- Open Access
- 17 September 2026
- Published by SAGE Publications in Clinical Medicine Insights: Endocrinology and Diabetes
- Vol. 19
Translating CGM Regulatory Performance Metrics Into Clinical Interpretation: An Exploratory Expert Consensus Framework
Background: Continuous glucose monitoring (CGM) performance is characterized by technical metrics that are inconsistently standardized across regulatory frameworks and variably connected to clinically meaningful outcomes, complicating interpretation and cross-device comparison. Objectives: To develop an exploratory framework translating CGM performance characteristics and derived metrics into clinically interpretable domains while distinguishing empirical evidence from expert judgment. Methods: Candidate metrics were extracted from contemporary clinical, technical, and regulatory sources and organized into six functional domains. Targeted PubMed searches in ambulatory adults with diabetes evaluated domain-specific technical-to-clinical questions. Evidence was classified as direct device-performance, direct between-device comparative, or indirect/contextual. Five experts participated in two private voting rounds using a virtual Nominal Group Technique and prespecified RAND/UCLA agreement criteria. The study was conducted from November 2025 to January 2026. Results: More than 30 metrics and attributes were mapped across analytical accuracy and performance, glycemic exposure, glycemic variability, clinical safety, adherence and device use, and device reliability. Direct evidence was most clearly identified for device-level analytical performance and between-device differences in analytical accuracy and glycemic exposure; evidence in other domains was predominantly indirect, contextual, or device-specific. Twenty-four of 25 statements achieved consensus after round 1 and all 25 after round 2. The panel considered dynamic accuracy, alert functionality when available, and monitoring continuity potentially clinically meaningful, but these ratings did not establish category-wide superiority of FDA-designated integrated CGM systems. Conclusion: The framework provides an exploratory structure for interpreting CGM technical performance and derived metrics. Regulatory designation and individual device characteristics should be considered separately, and purpose-designed comparative studies are required to determine whether specific attributes produce reproducible clinical benefits.
- 17 September 2026
- Published by SAGE Publications in Clinical Medicine Insights: Endocrinology and Diabetes
- Vol. 19
Open AccessTranslating CGM Regulatory Performance Metrics Into Clinical Interpretation: An Exploratory Expert Consensus Framework
Background: Continuous glucose monitoring (CGM) performance is characterized by technical metrics that are inconsistently standardized across regulatory frameworks and variably connected to clinically meaningful outcomes, complicating interpretation and cross-device comparison. Objectives: To develop an exploratory framework translating CGM performance characteristics and derived metrics into clinically interpretable domains while distinguishing empirical evidence from expert judgment. Methods: Candidate metrics were extracted from contemporary clinical, technical, and regulatory sources and organized into six functional domains. Targeted PubMed searches in ambulatory adults with diabetes evaluated domain-specific technical-to-clinical questions. Evidence was classified as direct device-performance, direct between-device comparative, or indirect/contextual. Five experts participated in two private voting rounds using a virtual Nominal Group Technique and prespecified RAND/UCLA agreement criteria. The study was conducted from November 2025 to January 2026. Results: More than 30 metrics and attributes were mapped across analytical accuracy and performance, glycemic exposure, glycemic variability, clinical safety, adherence and device use, and device reliability. Direct evidence was most clearly identified for device-level analytical performance and between-device differences in analytical accuracy and glycemic exposure; evidence in other domains was predominantly indirect, contextual, or device-specific. Twenty-four of 25 statements achieved consensus after round 1 and all 25 after round 2. The panel considered dynamic accuracy, alert functionality when available, and monitoring continuity potentially clinically meaningful, but these ratings did not establish category-wide superiority of FDA-designated integrated CGM systems. Conclusion: The framework provides an exploratory structure for interpreting CGM technical performance and derived metrics. Regulatory designation and individual device characteristics should be considered separately, and purpose-designed comparative studies are required to determine whether specific attributes produce reproducible clinical benefits.
- Open Access
- 7 June 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (7) , 1067-1083
Dose–Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis
Semaglutide and tirzepatide are highly effective incretin-based therapies for weight reduction in individuals with type 2 diabetes (T2DM). However, direct comparisons across the full range of clinically relevant doses in T2DM are limited. This study aimed to evaluate dose-response relationships and clinical equivalence between semaglutide and tirzepatide using a model-based approach. Arm-level data from phase III randomized controlled trials of semaglutide (SUSTAIN, STEP) and tirzepatide (SURPASS, SURMOUNT-2) in T2DM were analyzed. Dose-response relationships for percent weight change were modeled using generalized additive models and Bayesian hierarchical spline models. Posterior probabilities of clinical equivalence were estimated across prespecified dose pairs using an equivalence margin of ± 2 percentage points. Model-based intensification scenarios were evaluated to estimate incremental benefit associated with treatment switching or dose escalation. A total of 48 treatment arms (n = 16,524 participants) were included. Both agents demonstrated nonlinear dose-response relationships, with attenuation of incremental effects at higher doses. High probabilities of equivalence were observed for semaglutide 2.4 mg versus tirzepatide 10 mg (99.4%) and semaglutide 7.2 mg versus tirzepatide 15 mg (94.8%). Lower doses of semaglutide were not equivalent to higher doses of tirzepatide. In intensification scenarios, both switching and dose escalation strategies improved weight loss, although the probability of achieving ≥ 2 additional percentage points varied across regimens. Semaglutide and tirzepatide demonstrate comparable weight-loss efficacy at specific dose combinations, with equivalence driven by dose rather than drug identity. Model-based analyses provide a quantitative framework to support individualized treatment decisions when direct comparative evidence is unavailable.
- 7 June 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (7) , 1067-1083
Open AccessDose–Response and Clinical Equivalence of Semaglutide and Tirzepatide for Weight Loss in Type 2 Diabetes: A Model-Based Analysis
Semaglutide and tirzepatide are highly effective incretin-based therapies for weight reduction in individuals with type 2 diabetes (T2DM). However, direct comparisons across the full range of clinically relevant doses in T2DM are limited. This study aimed to evaluate dose-response relationships and clinical equivalence between semaglutide and tirzepatide using a model-based approach. Arm-level data from phase III randomized controlled trials of semaglutide (SUSTAIN, STEP) and tirzepatide (SURPASS, SURMOUNT-2) in T2DM were analyzed. Dose-response relationships for percent weight change were modeled using generalized additive models and Bayesian hierarchical spline models. Posterior probabilities of clinical equivalence were estimated across prespecified dose pairs using an equivalence margin of ± 2 percentage points. Model-based intensification scenarios were evaluated to estimate incremental benefit associated with treatment switching or dose escalation. A total of 48 treatment arms (n = 16,524 participants) were included. Both agents demonstrated nonlinear dose-response relationships, with attenuation of incremental effects at higher doses. High probabilities of equivalence were observed for semaglutide 2.4 mg versus tirzepatide 10 mg (99.4%) and semaglutide 7.2 mg versus tirzepatide 15 mg (94.8%). Lower doses of semaglutide were not equivalent to higher doses of tirzepatide. In intensification scenarios, both switching and dose escalation strategies improved weight loss, although the probability of achieving ≥ 2 additional percentage points varied across regimens. Semaglutide and tirzepatide demonstrate comparable weight-loss efficacy at specific dose combinations, with equivalence driven by dose rather than drug identity. Model-based analyses provide a quantitative framework to support individualized treatment decisions when direct comparative evidence is unavailable.
- Open Access
- 26 May 2026
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 13 (2)
Enfermedad cardiovascular en pacientes con acromegalia: una revisión narrativa
Contexto: la acromegalia es una enfermedad rara causada principalmente por adenomas hipofisarios secretores de hormona del crecimiento (GH), la cual tiene múltiples manifestaciones sistémicas, entre las que el compromiso cardiovascular constituye la principal causa de morbilidad y mortalidad. Objetivo: describir la epidemiología y la fisiopatología de la enfermedad cardiovascular en pacientes con acromegalia, así como revisar el impacto del control hormonal en este escenario. Metodología: se realizó una búsqueda bibliográfica en PubMed, Scielo y Google Scholar hasta enero de 2025, utilizando los términos acromegalia, enfermedad cardiovascular, hipertensión, diabetes mellitus, dislipidemia, arritmia, valvulopatía, cardiomiopatía, enfermedad coronaria y enfermedad cerebrovascular. Se incluyeron artículos originales, ensayos clínicos, revisiones sistemáticas y metaanálisis. Se excluyeron publicaciones que no estuvieran disponibles en inglés o español. Resultados: el exceso de la hormona del crecimiento e IGF-1 se asocia a una elevada prevalencia de comorbilidades cardiovasculares, como la hipertensión arterial, presente en el 50–64 % de los pacientes, seguida de la dislipidemia, que afecta a más del 60 %, y la diabetes mellitus, presente en aproximadamente el 30 %. Las arritmias cardíacas se presentan en el 7–40 % de los casos y las valvulopatías moderadas a severas en el 6–11 %, las cuales se asocian a hipertrofia ventricular y fibrosis miocárdica. El control bioquímico mediante cirugía o tratamiento farmacológico puede mejorar factores de riesgo como la presión arterial y el perfil lipídico; sin embargo, la evidencia sobre su impacto en la reducción de eventos cardiovasculares mayores es heterogénea. Conclusiones: el compromiso cardiovascular en la acromegalia es frecuente y relevante. Aunque el control hormonal mejora algunos parámetros metabólicos, su efecto sobre desenlaces cardiovasculares mayores, como la muerte, el infarto agudo de miocardio y la enfermedad cerebrovascular, sigue siendo incierto. Se requiere un abordaje integral enfocado en el control hormonal y la optimización de factores de riesgo tradicionales, así como estudios prospectivos que definan con mayor claridad el impacto terapéutico en desenlaces clínicos significativos.
- 26 May 2026
- Published by Asociacion Colombiana de Endocrinologia, Diabetes y Metabolismo in Revista Colombiana de Endocrinología, Diabetes & Metabolismo
- Vol. 13 (2)
Open AccessEnfermedad cardiovascular en pacientes con acromegalia: una revisión narrativa
Contexto: la acromegalia es una enfermedad rara causada principalmente por adenomas hipofisarios secretores de hormona del crecimiento (GH), la cual tiene múltiples manifestaciones sistémicas, entre las que el compromiso cardiovascular constituye la principal causa de morbilidad y mortalidad. Objetivo: describir la epidemiología y la fisiopatología de la enfermedad cardiovascular en pacientes con acromegalia, así como revisar el impacto del control hormonal en este escenario. Metodología: se realizó una búsqueda bibliográfica en PubMed, Scielo y Google Scholar hasta enero de 2025, utilizando los términos acromegalia, enfermedad cardiovascular, hipertensión, diabetes mellitus, dislipidemia, arritmia, valvulopatía, cardiomiopatía, enfermedad coronaria y enfermedad cerebrovascular. Se incluyeron artículos originales, ensayos clínicos, revisiones sistemáticas y metaanálisis. Se excluyeron publicaciones que no estuvieran disponibles en inglés o español. Resultados: el exceso de la hormona del crecimiento e IGF-1 se asocia a una elevada prevalencia de comorbilidades cardiovasculares, como la hipertensión arterial, presente en el 50–64 % de los pacientes, seguida de la dislipidemia, que afecta a más del 60 %, y la diabetes mellitus, presente en aproximadamente el 30 %. Las arritmias cardíacas se presentan en el 7–40 % de los casos y las valvulopatías moderadas a severas en el 6–11 %, las cuales se asocian a hipertrofia ventricular y fibrosis miocárdica. El control bioquímico mediante cirugía o tratamiento farmacológico puede mejorar factores de riesgo como la presión arterial y el perfil lipídico; sin embargo, la evidencia sobre su impacto en la reducción de eventos cardiovasculares mayores es heterogénea. Conclusiones: el compromiso cardiovascular en la acromegalia es frecuente y relevante. Aunque el control hormonal mejora algunos parámetros metabólicos, su efecto sobre desenlaces cardiovasculares mayores, como la muerte, el infarto agudo de miocardio y la enfermedad cerebrovascular, sigue siendo incierto. Se requiere un abordaje integral enfocado en el control hormonal y la optimización de factores de riesgo tradicionales, así como estudios prospectivos que definan con mayor claridad el impacto terapéutico en desenlaces clínicos significativos.
- 16 April 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (6)
Predictive model for the diagnosis of ectopic Cushing syndrome
The purpose of our study was to develop and externally validate a multivariable diagnostic model to distinguish ectopic ACTH secretion (EAS) from Cushing’s disease (CD) using routine clinical parameters. The model was derived from a Spanish multicenter retrospective cohort and externally validated in a Colombian cohort. Predictors were selected through a multivariable logistic regression model with penalized logistic regression (LASSO) using the Spanish cohort. Discriminative performance was assessed using the area under the ROC curve (AUC) and calibration using the slope, the origin, and the Brier score. The derivation cohort included 253 patients from Spain (199 with CD and 54 with EAS). The external validation cohort comprised 72 Colombian patients (53 with CD and 19 with EAS). In the derivation cohort, multivariable modeling identified four independent predictors: ACTH concentration, 24-h urinary free cortisol (UFC), serum potassium, and maximum pituitary tumor diameter. The final model demonstrated good discrimination in the derivation cohort (mean AUC of 0.987), with excellent calibration (calibration slope ranged from 0.998 to 5.22, intercept −0.2 to 0.99, Brier score 0.035). In external validation, model performance remained robust (AUC ranging from 0.9885 to 0.9890; Brier score 0.0381). The model achieved a sensitivity of 95.3%, specificity of 93.6%, positive predictive value of 82.3%, and negative predictive value of 98.7% for detecting EAS. Thus, the diagnostic model developed, based on routinely available clinical variables, shows high accuracy and calibration in differentiating between EAS and CD, supporting its potential use in diverse clinical settings and integration into diagnostic workflows.
- 16 April 2026
- Published by Bioscientifica in Endocrine-Related Cancer
- Vol. 33 (6)
Predictive model for the diagnosis of ectopic Cushing syndrome
The purpose of our study was to develop and externally validate a multivariable diagnostic model to distinguish ectopic ACTH secretion (EAS) from Cushing’s disease (CD) using routine clinical parameters. The model was derived from a Spanish multicenter retrospective cohort and externally validated in a Colombian cohort. Predictors were selected through a multivariable logistic regression model with penalized logistic regression (LASSO) using the Spanish cohort. Discriminative performance was assessed using the area under the ROC curve (AUC) and calibration using the slope, the origin, and the Brier score. The derivation cohort included 253 patients from Spain (199 with CD and 54 with EAS). The external validation cohort comprised 72 Colombian patients (53 with CD and 19 with EAS). In the derivation cohort, multivariable modeling identified four independent predictors: ACTH concentration, 24-h urinary free cortisol (UFC), serum potassium, and maximum pituitary tumor diameter. The final model demonstrated good discrimination in the derivation cohort (mean AUC of 0.987), with excellent calibration (calibration slope ranged from 0.998 to 5.22, intercept −0.2 to 0.99, Brier score 0.035). In external validation, model performance remained robust (AUC ranging from 0.9885 to 0.9890; Brier score 0.0381). The model achieved a sensitivity of 95.3%, specificity of 93.6%, positive predictive value of 82.3%, and negative predictive value of 98.7% for detecting EAS. Thus, the diagnostic model developed, based on routinely available clinical variables, shows high accuracy and calibration in differentiating between EAS and CD, supporting its potential use in diverse clinical settings and integration into diagnostic workflows.
- Open Access
- 28 March 2026
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 17
Clinical characteristics, diagnosis, and treatment of Cushing’s syndrome: analysis of a multicenter registry in Antioquia, Colombia
Background: Cushing’s syndrome (CS) is a rare endocrine disorder caused by long-term exposure to excess cortisol and is linked to significant morbidity. Data from multiple centers in Latin America remains limited. Objectives: To describe the clinical, diagnostic, and treatment characteristics of patients with CS in a regional Colombian cohort and to assess surgical outcomes in patients with Cushing’s disease (CD) based on neurosurgical expertise. Design: Multicenter retrospective cohort study. Methods: Medical records from six hospitals in Antioquia, Colombia, were reviewed, including adult patients with biochemically confirmed endogenous CS diagnosed between 2010 and 2024. Data collected included sociodemographic, clinical features, diagnostic tests, etiological classification, treatments, and outcomes. In patients with CD, surgical remission, recurrence, persistence, and postoperative complications were compared based on neurosurgical expertise. Results: A total of 130 patients were included; 86.9% were women, with an average age of 50.7 years. The most common presenting features were weight gain (79.2%), moon face (36.9%), and striae (29.2%). CD was the leading cause (74.6%), followed by adrenal CS (17.6%) and ectopic adrenocorticotropic hormone syndrome (1.5%). The most frequently used diagnostic tests were 24-h urinary free cortisol and the 1-mg overnight dexamethasone suppression test, while late-night salivary cortisol and inferior petrosal sinus sampling were less commonly performed. Transsphenoidal surgery in CD achieved an initial remission rate of 63.3%, with no significant differences based on neurosurgical experience. All cases of adrenal CS underwent unilateral adrenalectomy. Conclusion: In this Colombian multicenter cohort, the clinical features, etiological distribution, and surgical outcomes in CS and CD were similar to those reported in specialized international centers. These findings highlight the importance of early detection, better access to diagnostic tools, and multidisciplinary care to improve outcomes in this rare disease.
- 28 March 2026
- Published by SAGE Publications in Therapeutic Advances in Endocrinology and Metabolism
- Vol. 17
Open AccessClinical characteristics, diagnosis, and treatment of Cushing’s syndrome: analysis of a multicenter registry in Antioquia, Colombia
Background: Cushing’s syndrome (CS) is a rare endocrine disorder caused by long-term exposure to excess cortisol and is linked to significant morbidity. Data from multiple centers in Latin America remains limited. Objectives: To describe the clinical, diagnostic, and treatment characteristics of patients with CS in a regional Colombian cohort and to assess surgical outcomes in patients with Cushing’s disease (CD) based on neurosurgical expertise. Design: Multicenter retrospective cohort study. Methods: Medical records from six hospitals in Antioquia, Colombia, were reviewed, including adult patients with biochemically confirmed endogenous CS diagnosed between 2010 and 2024. Data collected included sociodemographic, clinical features, diagnostic tests, etiological classification, treatments, and outcomes. In patients with CD, surgical remission, recurrence, persistence, and postoperative complications were compared based on neurosurgical expertise. Results: A total of 130 patients were included; 86.9% were women, with an average age of 50.7 years. The most common presenting features were weight gain (79.2%), moon face (36.9%), and striae (29.2%). CD was the leading cause (74.6%), followed by adrenal CS (17.6%) and ectopic adrenocorticotropic hormone syndrome (1.5%). The most frequently used diagnostic tests were 24-h urinary free cortisol and the 1-mg overnight dexamethasone suppression test, while late-night salivary cortisol and inferior petrosal sinus sampling were less commonly performed. Transsphenoidal surgery in CD achieved an initial remission rate of 63.3%, with no significant differences based on neurosurgical experience. All cases of adrenal CS underwent unilateral adrenalectomy. Conclusion: In this Colombian multicenter cohort, the clinical features, etiological distribution, and surgical outcomes in CS and CD were similar to those reported in specialized international centers. These findings highlight the importance of early detection, better access to diagnostic tools, and multidisciplinary care to improve outcomes in this rare disease.
- Open Access
- 18 March 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (4) , 499-528
Renal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review
Diabetes mellitus is the leading global cause of chronic kidney disease (CKD) and end-stage renal disease. Although cardiovascular outcomes have improved substantially, renal risk remains high. Glucagon-like peptide 1 (GLP-1) receptor agonists and the dual GLP-1/GIP agonist tirzepatide have demonstrated potential cardiorenal benefits, but renal evidence has not been systematically mapped across CKD stages and metabolic phenotypes. This scoping review aimed to identify and describe clinical evidence on renal outcomes associated with GLP-1-based therapies in adults with type 2 diabetes and/or overweight/obesity, with or without CKD. Following the Joanna Briggs Institute framework and PRISMA-ScR guidelines (protocol: OSF.IO/SZ87J), we searched PubMed, Embase, and CENTRAL from inception to October 2025. Eligible studies included phase 2-4 randomized controlled trials (RCTs), post hoc RCT analyses, and comparative observational studies reporting kidney outcomes. Data were charted using a structured extraction form with AI-assisted screening and manual validation. Risk of bias and certainty were appraised using RoB 2, ROBINS-I, and GRADE frameworks. Of 607 records identified, 35 studies met inclusion criteria. Randomized evidence supports renal benefits for semaglutide, dulaglutide, and liraglutide, including reductions in composite kidney outcomes and slower eGFR decline. Tirzepatide demonstrated consistent albuminuria reductions and attenuation of eGFR decline compared with insulin glargine. Efpeglenatide, cotadutide, exenatide, and lixisenatide showed class-consistent antiproteinuric effects. Observational data extended findings to real-world and advanced CKD populations. Across agents, renal benefits were partly independent of glycemic and weight effects. GLP-1-based therapies demonstrate consistent renoprotective signals across CKD stages and metabolic phenotypes, particularly in type 2 diabetes. Evidence is strongest for semaglutide and dulaglutide, with emerging data for tirzepatide and other incretin-based agents. These findings provide a structured evidence map to inform future consensus and clinical decision-making.
- 18 March 2026
- Published by Springer Nature in Diabetes Therapy
- Vol. 17 (4) , 499-528
Open AccessRenal Outcomes of GLP-1 Receptor Agonists and Tirzepatide Across CKD Stages and Metabolic Phenotypes (Type 2 Diabetes and/or Overweight/Obesity): A Scoping Review
Diabetes mellitus is the leading global cause of chronic kidney disease (CKD) and end-stage renal disease. Although cardiovascular outcomes have improved substantially, renal risk remains high. Glucagon-like peptide 1 (GLP-1) receptor agonists and the dual GLP-1/GIP agonist tirzepatide have demonstrated potential cardiorenal benefits, but renal evidence has not been systematically mapped across CKD stages and metabolic phenotypes. This scoping review aimed to identify and describe clinical evidence on renal outcomes associated with GLP-1-based therapies in adults with type 2 diabetes and/or overweight/obesity, with or without CKD. Following the Joanna Briggs Institute framework and PRISMA-ScR guidelines (protocol: OSF.IO/SZ87J), we searched PubMed, Embase, and CENTRAL from inception to October 2025. Eligible studies included phase 2-4 randomized controlled trials (RCTs), post hoc RCT analyses, and comparative observational studies reporting kidney outcomes. Data were charted using a structured extraction form with AI-assisted screening and manual validation. Risk of bias and certainty were appraised using RoB 2, ROBINS-I, and GRADE frameworks. Of 607 records identified, 35 studies met inclusion criteria. Randomized evidence supports renal benefits for semaglutide, dulaglutide, and liraglutide, including reductions in composite kidney outcomes and slower eGFR decline. Tirzepatide demonstrated consistent albuminuria reductions and attenuation of eGFR decline compared with insulin glargine. Efpeglenatide, cotadutide, exenatide, and lixisenatide showed class-consistent antiproteinuric effects. Observational data extended findings to real-world and advanced CKD populations. Across agents, renal benefits were partly independent of glycemic and weight effects. GLP-1-based therapies demonstrate consistent renoprotective signals across CKD stages and metabolic phenotypes, particularly in type 2 diabetes. Evidence is strongest for semaglutide and dulaglutide, with emerging data for tirzepatide and other incretin-based agents. These findings provide a structured evidence map to inform future consensus and clinical decision-making.
- Open Access
- 11 March 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Quality of life questionnaires in patients with acromegaly: a scoping review
Introduction: Acromegaly is a rare disease caused by a pituitary adenoma in most cases. Physical changes, metabolic disturbances, osteoarticular symptoms, as well as psychological and social repercussions reduce the Quality of Life (QoL) of people suffering from the disease. Objective: To assess both generic and disease-specific instruments employed to capture the influence of acromegaly on patients’ QoL. Methods and analysis: This scoping review assessed the different tools used to evaluate QoL in people with acromegaly. This review followed the methods proposed by the Joanna Briggs Institute and is reported following the Preferred Reporting Items for Systematic Reviews manual and Meta-Analyses extension for Scoping Reviews. Results: Of a total of 198 studies, 30 questionnaires were identified and categorized by type (specific or generic) and number of domains assessed (physical health, psychological state, autonomy, and social relationships). Among these, 3 were specific-multidomain, 18 generic-multidomain, 3 specific-unidomain, 5 generic-unidomain, and only 1 had no domains. All were patient-reported outcome measures (PROM) used in various contexts. Optimal instruments were disease-specific, multidimensional, brief, easily administered, available in multiple languages, with psychometric validation in acromegaly patients and cross-cultural validation, and assessing treatment impact on QoL. Conclusions: This review explores the use of PROMs in assessing HRQoL in acromegaly patients, emphasizing the need for specific, validated, and culturally adapted tools addressing symptoms and treatment impact. We propose a novel domain-based classification to overcome existing limitations of instruments and improve their presentation in future studies. This study provides a synthesis that helps advance research and guide clinical practices around HRQoL in acromegaly management.
- 11 March 2026
- Published by Springer Nature in Journal of Patient-Reported Outcomes
- Vol. 10 (1)
Open AccessQuality of life questionnaires in patients with acromegaly: a scoping review
Introduction: Acromegaly is a rare disease caused by a pituitary adenoma in most cases. Physical changes, metabolic disturbances, osteoarticular symptoms, as well as psychological and social repercussions reduce the Quality of Life (QoL) of people suffering from the disease. Objective: To assess both generic and disease-specific instruments employed to capture the influence of acromegaly on patients’ QoL. Methods and analysis: This scoping review assessed the different tools used to evaluate QoL in people with acromegaly. This review followed the methods proposed by the Joanna Briggs Institute and is reported following the Preferred Reporting Items for Systematic Reviews manual and Meta-Analyses extension for Scoping Reviews. Results: Of a total of 198 studies, 30 questionnaires were identified and categorized by type (specific or generic) and number of domains assessed (physical health, psychological state, autonomy, and social relationships). Among these, 3 were specific-multidomain, 18 generic-multidomain, 3 specific-unidomain, 5 generic-unidomain, and only 1 had no domains. All were patient-reported outcome measures (PROM) used in various contexts. Optimal instruments were disease-specific, multidimensional, brief, easily administered, available in multiple languages, with psychometric validation in acromegaly patients and cross-cultural validation, and assessing treatment impact on QoL. Conclusions: This review explores the use of PROMs in assessing HRQoL in acromegaly patients, emphasizing the need for specific, validated, and culturally adapted tools addressing symptoms and treatment impact. We propose a novel domain-based classification to overcome existing limitations of instruments and improve their presentation in future studies. This study provides a synthesis that helps advance research and guide clinical practices around HRQoL in acromegaly management.
- Open Access
- 28 February 2026
- Published by SAGE Publications in Clinical Medicine Insights: Endocrinology and Diabetes
- Vol. 19
Pharmacologic Therapies for Active Moderate-to-Severe TED: A Comprehensive Systematic Review
Background: Moderate-to-severe thyroid eye disease (TED) is a potentially vision-threatening inflammatory condition that requires timely, evidence-based medical management. Although intravenous glucocorticoids remain the mainstay of therapy, several biologic and immunosuppressive agents have emerged as potential alternatives, particularly in steroid-refractory disease. Objectives: To evaluate and compare the efficacy, safety, and therapeutic positioning of medical treatments for active moderate-to-severe thyroid eye disease. Data Sources and Methods: A comprehensive search of PubMed, Embase, and the Cochrane Library was conducted through February 2025. Eligible studies included randomized controlled trials, meta-analyses, systematic reviews, observational cohorts, and selected case series evaluating pharmacological interventions for moderate-to-severe TED. Outcomes of interest were proptosis reduction, Clinical Activity Score (CAS) improvement, diplopia response, and safety/tolerability. A semi-quantitative synthesis approach was used to integrate evidence across heterogeneous study designs. Results: Fifty-eight studies met the inclusion criteria. Intravenous glucocorticoids (IVGCs) demonstrated the most consistent efficacy in controlling inflammatory activity, with modest effects on proptosis and favorable tolerability at cumulative doses below 8 g. Among biologic therapies, teprotumumab showed the greatest magnitude of benefit across all efficacy domains but was limited by safety considerations and access constraints. Rituximab and tocilizumab demonstrated moderate efficacy, particularly in glucocorticoid-resistant cases. Mycophenolate mofetil emerged as the most reliable non-biologic immunosuppressive option. Oral glucocorticoids and several adjunctive therapies showed limited or inconsistent benefit. Conclusion: This systematic review provides an integrated framework to support therapeutic decision-making in moderate-to-severe TED. Intravenous glucocorticoids remain the most consistently supported first-line therapy, while IGF-1R–targeted biologic therapy offers the most comprehensive efficacy across key clinical domains in selected patients. Registration: Not registered.
- 28 February 2026
- Published by SAGE Publications in Clinical Medicine Insights: Endocrinology and Diabetes
- Vol. 19
Open AccessPharmacologic Therapies for Active Moderate-to-Severe TED: A Comprehensive Systematic Review
Background: Moderate-to-severe thyroid eye disease (TED) is a potentially vision-threatening inflammatory condition that requires timely, evidence-based medical management. Although intravenous glucocorticoids remain the mainstay of therapy, several biologic and immunosuppressive agents have emerged as potential alternatives, particularly in steroid-refractory disease. Objectives: To evaluate and compare the efficacy, safety, and therapeutic positioning of medical treatments for active moderate-to-severe thyroid eye disease. Data Sources and Methods: A comprehensive search of PubMed, Embase, and the Cochrane Library was conducted through February 2025. Eligible studies included randomized controlled trials, meta-analyses, systematic reviews, observational cohorts, and selected case series evaluating pharmacological interventions for moderate-to-severe TED. Outcomes of interest were proptosis reduction, Clinical Activity Score (CAS) improvement, diplopia response, and safety/tolerability. A semi-quantitative synthesis approach was used to integrate evidence across heterogeneous study designs. Results: Fifty-eight studies met the inclusion criteria. Intravenous glucocorticoids (IVGCs) demonstrated the most consistent efficacy in controlling inflammatory activity, with modest effects on proptosis and favorable tolerability at cumulative doses below 8 g. Among biologic therapies, teprotumumab showed the greatest magnitude of benefit across all efficacy domains but was limited by safety considerations and access constraints. Rituximab and tocilizumab demonstrated moderate efficacy, particularly in glucocorticoid-resistant cases. Mycophenolate mofetil emerged as the most reliable non-biologic immunosuppressive option. Oral glucocorticoids and several adjunctive therapies showed limited or inconsistent benefit. Conclusion: This systematic review provides an integrated framework to support therapeutic decision-making in moderate-to-severe TED. Intravenous glucocorticoids remain the most consistently supported first-line therapy, while IGF-1R–targeted biologic therapy offers the most comprehensive efficacy across key clinical domains in selected patients. Registration: Not registered.